PF-219,061
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Nasal |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.295 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?) (verify) |
|
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It was under development as a potential medication for the treatment of female sexual dysfunction.[3][4] It did not advance into clinical trials.[5]
See also[edit]
- ABT-670
- ABT-724
- Cabergoline
- Bremelanotide
- Flibanserin
- Intrinsa
- Melanotan II
- OSU-6162
- PF-592,379
- Pramipexole
- Tibolone
- UK-414,495
References[edit]
- ^ Blagg, J; Allerton, C. M.; Batchelor, D. V.; Baxter, A. D.; Burring, D. J.; Carr, C. L.; Cook, A. S.; Nichols, C. L.; Phipps, J; Sanderson, V. G.; Verrier, H; Wong, S (2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691–6. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.
- ^ Brioni, Jorge D.; Moreland, Robert B. (2006). "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies. 3 (4): 599. doi:10.1016/j.ddstr.2006.10.006.
- ^ Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer
- ^ Attkins, N. J.; Heatherington, A. C.; Phipps, J; Verrier, H; Huyghe, I (2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica. 39 (7): 523–33. doi:10.1080/00498250902893775. PMID 19480558.
- ^ Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, Enric I. Canela, and Vicent Casadó (2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery. 11 (7): 641–64. doi:10.1080/17460441.2016.1185413. PMID 27135354.
